Recursion Pharmaceuticals owns the largest supercomputer in the pharmaceutical industry. However, Eli Lilly is starting to build one that could be even more powerful once it's completed. With its ...

Recursive Superintelligence Inc., a startup that hopes to develop self-improving artificial intelligence models, launched today with $650 million in funding. Alphabet Inc.’s GV fund and Greycroft led ...

Blockchain technology continues to evolve rapidly with scalability and efficiency as key challenges. Recursive SNARKs (Succinct Non-Interactive Arguments of Knowledge) have emerged as a breakthrough ...

When Google encounters `noindex`, it may skip rendering and JavaScript execution. JavaScript that tries to remove or change `noindex` may not run for Googlebot on that crawl. If you want a page ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

Recursion Pharmaceuticals (NASDAQ: RXRX) has been a pioneer in using artificial intelligence (AI) to improve the drug discovery process. The company, founded in 2013, has been working on that project ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

Recursion Pharmaceuticals developed a promising artificial intelligence (AI) platform for drug discovery and development. The company's clinical-stage pipeline is just the tip of the iceberg of its ...